The Firm represented Morgan Stanley & Co. International plc, as dealer manager, in concurrent transactions by Pfizer Inc. in which Pfizer (i) offered to exchange any and all of its existing 6.5% Notes due 2038 held by eligible holders for newly issued 2.735% Notes due 2043 and, alternatively, offered to purchase for cash any and all of its outstanding 6.5% Notes due 2038, and (ii) offered to purchase for cash any and all of its outstanding 5.75% Notes due 2021 and solicited consents to amendments to the related indenture.
Pfizer is a research-based, global biopharmaceutical company. Pfizer’s global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products.
The Simpson Thacher team included John D. Lobrano, Joe Kaufman, Jonathan Ozner and Yoonji Woo (Capital Markets); Jacqueline Clinton and Brian Mendick (Tax); Marcela Robledo (Intellectual Property); Jamin Koslowe (Executive Compensation and Employee Benefits); Adeeb Fadil and Noreen Lavan (Environmental); and Jennie Getsin (FINRA and Blue Sky).